VBL Therapeutics Presents Two Studies on Novel Anti-Angiogenic Vector at 102nd Annual AACR Meeting
3/31/2011 9:29:36 AM
TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company’s VB-111 program at the American Association for Cancer Research (AACR) 102nd Annual Meeting. Eyal Breitbart, Ph.D., vice president of research at VBL Therapeutics, is scheduled to present a poster entitled “VB-111 a Novel Anti-angiogenic Vector and a Promising Treatment for Metastatic Cancer in Combination with Other Anticancer Drugs” on Tuesday, April 5, 2011 at 8:00 a.m. EDT in Orlando, FL. Andrew J. Brenner, M.D., Ph.D., Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, is scheduled to present a poster entitled “Antiangiogenic gene therapy with VB-111 is Active in Glioblastoma Xenografts” on Wednesday, April 6, 2011 at 8:00 a.m. EDT.